IDEAYA Biosciences Inc (NAS:IDYA)
$ 26.66 -0.79 (-2.88%) Market Cap: 2.30 Bil Enterprise Value: 1.47 Bil PE Ratio: 0 PB Ratio: 1.95 GF Score: 30/100

IDEAYA Biosciences Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 / 05:00PM GMT
Release Date Price: $17.77 (+4.53%)
Maury Raycroft
Jefferies, LLC - Analyst

Hi everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Yujiro Hata, the CEO of IDEAYA Biosciences. Thanks so much for joining us today, Yujiro, in London.

Yujiro Hata
IDEAYA Biosciences, Inc. - CEO

Yeah, Maury, thanks for the kind introduction, and thank you for Jefferies again for the invitation. Great to be back here in London with everyone back in person. So thank you.

Questions & Answers

Maury Raycroft
Jefferies, LLC - Analyst

And we'll do a fireside chat. So maybe to start off, if you can provide a one-minute intro highlighting your main clinical candidates and key catalysts ahead?

Yujiro Hata
IDEAYA Biosciences, Inc. - CEO

Sure. So today, we have two programs in the clinic, darovasertib, which is in Phase 2. We recently presented a fairly robust Phase 2 efficacy data set in combination with Pfizer's quizartinib. The key catalysts for that program upcoming

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot